Aclaris Therapeutics (ACRS) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Q3 revenue was $1.481M and net loss was $18.510M; 9M revenue was $5.106M and net loss was $59.839M, with higher R&D expense contributing to wider losses.
ATI-052 reported positive Phase 1b results in atopic dermatitis and asthma; bosakitug Phase 2 top-line results and other pipeline milestones are expected in Q4 2026.
Cash, cash equivalents and marketable securities totaled $204.607M at quarter-end; October financing generated $46.7M net proceeds.
Financial highlights
Q3 revenue was $1.481M vs. $3.299M YoY; 9M revenue was $5.106M vs. $6.531M, primarily reflecting a prior-year Sun Pharma sales milestone.
Q3 net loss was $18.510M vs. $14.614M; 9M net loss was $59.839M vs. $45.128M. Operating loss was $21.344M in Q3 and $67.774M for 9M.
Q3 R&D expense was $16.066M vs. $13.028M; 9M R&D expense was $49.789M vs. $36.061M, mainly reflecting ATI-052 and ATI-9494 development and manufacturing costs.
9M net cash used in operating activities was $62.076M vs. $33.982M, reflecting higher adjusted net losses and lower cash received from operating assets.
Outlook and guidance
Top-line results from the 109-patient Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis are expected in Q4 2026.
Modzatinib Phase 2b in lichen planus is expected to initiate in Q4 2026; first site activation was expected in November.
ATI-9494 IND filing remains on track for Q4 2026.
ATI-052 is initially prioritized for a Phase 2b EoE trial planned for early 2027; selection of an additional Phase 2b indication is expected shortly.
Following the October offering, available cash and securities are expected to fund operations through H1 2029, excluding potential business development or additional financing.
Latest events from Aclaris Therapeutics
- ATI-052 showed AD and asthma activity; next-stage development will prioritize EoE.ACRS
Study result - Multiple late-stage readouts and new trials in I&I set the stage for significant pipeline progress.ACRS
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss rose to $41.3M as R&D spending increased, with $170.6M liquidity and major clinical milestones ahead.ACRS
Q2 2026 - Advancing TSLP biologics and ITK/JAK3 inhibitors with late 2026 clinical catalysts expected.ACRS
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Key bispecific and TSLP mAb data readouts expected in H2, with phase II asthma trial starting Q4.ACRS
Jefferies Global Healthcare Conference 2026 - All proposals passed, with board elections, compensation, and auditor ratification approved.ACRS
AGM 2026 - Multiple late-stage immunology assets advance toward key 2024 and 2026 milestones, backed by strong funding.ACRS
Bank of America Global Healthcare Conference 2026 - Lead assets show strong efficacy and safety in large immune disease markets, with cash runway to 2028.ACRS
Corporate presentation - ATI-052 offers best-in-class potency, long dosing intervals, and strong early efficacy data.ACRS
H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference